TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07607964: A Phase 1, First-in-Human, Single Ascending Dose, Open-label, Non-randomized Study Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of ABBV-519 in Subjects With Systemic Lupus Erythematosus (SLE) or Rheumato

Sponsor: AbbVie · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$281,520

Rescue Site Savings

+$187,680

Unlock Full NCT07607964 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07607964 Rescue Dossier →